Eli Lilly has amassed a $1.5 billion stockpile of its upcoming weight-loss drug, Orforglipron, anticipating FDA approval and rapid global distribution. The U.S. Senate Health Committee is investigating Apexus, questioning their profits and practices within the 340B Drug Discount Program designed to assist low-income individuals. Content creators should highlight the implications of pharmaceutical inventory strategies on market availability and the importance of regulatory oversight in public health programs.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



